Reports related to this article:
Project(s): View 3 related projects in PECWeb
Released August 13, 2024 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--French pharma company Sanofi (NASDAQ:SNY) (Paris, France) has confirmed plans to invest 1.3 billion euro (US$1.5 billion) to build a new insulin plant at its Frankfurt Höchst campus in Germany.
Sanofi, makers of Lantus-branded insulin, said the aim of the new facility will be to secure the long-term supply of insulin for people with diabetes and at the same time "strengthen European security of supply." It ends recent speculation that the company was planning to shift insulin manufacturing to France. The plant will cover an area of around 36,000 square meters, roughly the size of five football fields, and will replace existing manufacturing facilities at the site. It will add a "few hundred" more staff to the more than 4,000 people already employed at the campus when it is commissioned in 2029. The highly-automated plant promises an overhaul of processes, state-of-the-art digital and network solutions and the inclusion of renewable energy sources and passive waste reduction in buildings.
"With this project, we are reaffirming our commitment to diabetes patients worldwide and leveraging the many years of expertise at our Frankfurt BioCampus with its highly qualified employees," said Brendan O'Callaghan, Sanofi's global head of manufacturing and supply. "Sanofi has a long history of developing strategic platforms to secure the supply of important medicines and vaccines for the present and future. And our commitment to promoting European health sovereignty remains distinctive and unique . As one of the world's largest manufacturers of insulin, we remain committed to producing this essential medicine for the growing number of people with diabetes around the world."
The Sanofi BioCampus is one of the company's largest integrated manufacturing and distribution sites for insulins and a growing number of immunology biologics. It covers the entire insulin-production chain, from active ingredient production to the manufacture of cartridges and ampoules, the assembly of pens and auto-injectors. It currently supplies patients in about 80 countries with 20 different insulin products. Sanofi's new investment comes just two months after Industrial Info reported on the company's plan to spend more than 1.1 billion euro (US$1.2 billion) to boost its French bio-manufacturing operations. For additional information, see May 29, 2024, article--Sanofi Makes $1 Billion Investment in French Operations.
The company has benefitted from Germany's efforts to incentivise its pharma sector. Last year the government published its wide-ranging Pharmaceutical Strategy, which set out how it intends to reinvigorate Germany's role in the pharma sector by improving conditions for research and development, streamlining approval procedures and bolstering financial support for companies looking to build new plants or expand existing ones. Germany's Trade & Invest chief executive officer Robert Hermann said: "The Sanofi expansion is great news for Germany as a pharmaceuticals location and an expression of Germany's past and future strength in the area. The German government sees pharma as an economic pillar in the years to come, and the incentives and reforms it has promoted are encouraging some of the biggest names in the global industry to put their faith in the country. There's every reason to expect that more and more international companies will follow suit."
Other pharma majors that have announced significant German investments this year include Eli Lilly (NYSE:LLY) (Indianapolis, Indiana) and Japan's and Japan's Daiichi-Sankyo (Tokyo, Japan). Industrial Info is tracking Eli Lilly's plan to spend 2.3 billion euro (US$2.5 billion) to build its first German plant in the western town of Alzey as part of a global effort to meet rocketing demand for new diabetes and obesity therapies. Industrial Info is also tracking Daiichi Sankyo's planned investment of approximately US$1 billion into its Pfaffenhofen manufacturing facility near Munich to boost its capacity for producing antibody-drug conjugates (ADCs) and turn the site into "an international innovation center".
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
Sanofi, makers of Lantus-branded insulin, said the aim of the new facility will be to secure the long-term supply of insulin for people with diabetes and at the same time "strengthen European security of supply." It ends recent speculation that the company was planning to shift insulin manufacturing to France. The plant will cover an area of around 36,000 square meters, roughly the size of five football fields, and will replace existing manufacturing facilities at the site. It will add a "few hundred" more staff to the more than 4,000 people already employed at the campus when it is commissioned in 2029. The highly-automated plant promises an overhaul of processes, state-of-the-art digital and network solutions and the inclusion of renewable energy sources and passive waste reduction in buildings.
"With this project, we are reaffirming our commitment to diabetes patients worldwide and leveraging the many years of expertise at our Frankfurt BioCampus with its highly qualified employees," said Brendan O'Callaghan, Sanofi's global head of manufacturing and supply. "Sanofi has a long history of developing strategic platforms to secure the supply of important medicines and vaccines for the present and future. And our commitment to promoting European health sovereignty remains distinctive and unique . As one of the world's largest manufacturers of insulin, we remain committed to producing this essential medicine for the growing number of people with diabetes around the world."
The Sanofi BioCampus is one of the company's largest integrated manufacturing and distribution sites for insulins and a growing number of immunology biologics. It covers the entire insulin-production chain, from active ingredient production to the manufacture of cartridges and ampoules, the assembly of pens and auto-injectors. It currently supplies patients in about 80 countries with 20 different insulin products. Sanofi's new investment comes just two months after Industrial Info reported on the company's plan to spend more than 1.1 billion euro (US$1.2 billion) to boost its French bio-manufacturing operations. For additional information, see May 29, 2024, article--Sanofi Makes $1 Billion Investment in French Operations.
The company has benefitted from Germany's efforts to incentivise its pharma sector. Last year the government published its wide-ranging Pharmaceutical Strategy, which set out how it intends to reinvigorate Germany's role in the pharma sector by improving conditions for research and development, streamlining approval procedures and bolstering financial support for companies looking to build new plants or expand existing ones. Germany's Trade & Invest chief executive officer Robert Hermann said: "The Sanofi expansion is great news for Germany as a pharmaceuticals location and an expression of Germany's past and future strength in the area. The German government sees pharma as an economic pillar in the years to come, and the incentives and reforms it has promoted are encouraging some of the biggest names in the global industry to put their faith in the country. There's every reason to expect that more and more international companies will follow suit."
Other pharma majors that have announced significant German investments this year include Eli Lilly (NYSE:LLY) (Indianapolis, Indiana) and Japan's and Japan's Daiichi-Sankyo (Tokyo, Japan). Industrial Info is tracking Eli Lilly's plan to spend 2.3 billion euro (US$2.5 billion) to build its first German plant in the western town of Alzey as part of a global effort to meet rocketing demand for new diabetes and obesity therapies. Industrial Info is also tracking Daiichi Sankyo's planned investment of approximately US$1 billion into its Pfaffenhofen manufacturing facility near Munich to boost its capacity for producing antibody-drug conjugates (ADCs) and turn the site into "an international innovation center".
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
